Enlivex Announces Positive Interim DSMB Safety Review, Supporting Continued Enrollment in Phase IIb Knee Osteoarthritis Trial
Key Highlights
- ➤DSMB confirms Allocetra safety profile supports continued Phase IIb enrollment
- ➤Interim safety review covers 85 randomized and dosed knee osteoarthritis patients
- ➤Phase IIb trial plans approximately 182 patients across three countries
- ➤Trial evaluates three Allocetra injections against placebo in patients aged 64 and older
Expert Statements
Einat Galamidi, Chief Medical Officer of Enlivex
“The outcome of this interim review, covering 85 patients randomized and dosed in the trial, appears consistent with the favorable safety profile observed in our Phase I/IIa trial.”
Einat Galamidi, Chief Medical Officer of Enlivex
“We are pleased with the DSMB’s decision that the trial will continue as planned and designed, and we remain focused on executing the Phase IIb trial and look forward to reporting topline data.”
Nes-Ziona, Israel, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced that the independent Data and Safety Monitoring Board (DSMB) overseeing the Company's randomized, double-blind, placebo-controlled Phase IIb trial evaluating Allocetra™ in patients with primary age-related knee osteoarthritis has completed an interim safety review of data from 85 patients randomized and dosed in the trial. Following review of the data, the DSMB confirmed that the safety profile of Allocetra™ allows the Company to continue enrolling patients in the trial as planned.
“The outcome of this interim review, covering 85 patients randomized and dosed in the trial, appears consistent with the favorable safety profile observed in our Phase I/IIa trial,” said Einat Galamidi, Chief Medical Officer of Enlivex. “We are pleased with the DSMB’s decision that the trial will continue as planned and designed, and we remain focused on executing the Phase IIb trial and look forward to reporting topline data.”
Get started
Create a free account to read the full story.
